Investment: Problems under the surface at Zeneca
Friday 07 August 1998
It has a decent drugs portfolio - its asthma treatment Accolate is still the star performer - backed up by a pipeline with a couple of potential best-sellers. The agrochemicals division, which has been a drag on earnings for some time, is set to benefit from recent restructuring, with fungicides already delivering growth.
Add a problem-free balance sheet and you can see why the market believes Zeneca is strong enough to keep its promise of growing underlying earnings by 15 per cent a year.
Yesterday's first-half results, which showed a 2 per cent slide in profits to pounds 654m after a heavy hit from sterling, Asia and the millennium bug, did little to dent this belief. The shares firmed 15p to 2280p after a pretty poor run in the weeks leading up to the figures.
So can Zeneca be discharged with a clean bill of health? Not really. If investors scratch the surface, they will see that some of the star drugs - including two blockbusters, the hypertension treatment Zestril and the cancer drug Novaldex - are set to lose patent protection in 2002. The new compounds which were supposed to replace them, notably the schizophrenia drug Seroquel, have got off to a slow start while the mature ones will suffer from increased competition.
At the same time, the agrochemicals division will be hit by difficult market conditions and shrinking margins. True, Zeneca could be taken over by one of the pharmaceutical giants, but no credible suitor willing to pay a premium has materialised despite years of speculation. And with the shares trading at almost 30 times expected 1998 earnings of around pounds 1.1bn - a 60 per cent premium to the market - the prescription is: sell into strength.
Diving in at the deep end is no excuse for shirking the style stakes
- 1 World Cup 2014: 20 things we learned in Brazil
- 2 Why I'm on the brink of burning my Israeli passport
- 3 War is war: Why I stand with Israel
- 4 L'Oreal cuts ties with Belgium supporter Axelle Despiegelaere after hunting trip photographs
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Ian Thorpe gay: Olympic swimmer comes out in Parkinson interview
Pamplona bull run: Man who contributed to a survival guide for the festival falls foul of the raging beasts
Israel-Gaza conflict: William Hague calls for ceasefire but says Israel 'has the right to defend itself'
Supermoon 2014: When and why will the moon look bigger and brighter this summer?
Sustained immigration has not harmed Britons' employment, say government advisers
War is war: Why I stand with Israel
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Australia facing international condemnation after turning around Sri Lankans at sea
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
iJobs Money & Business
£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...
£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...
£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...
£35000 per annum: Harrington Starr: Service Desk Analyst (Windows, Active Dire...